The KCTD1 Knockout HT29 Polyclonal Cells are a versatile CRISPR/Cas9-edited polyclonal cell population designed for targeted disruption of the KCTD1 gene within the HT29 colorectal adenocarcinoma cell line. This product provides a heterogeneous loss-of-function model, enabling researchers to interrogate KCTD1-dependent cellular processes without the constraints of clonal selection. The polyclonal nature of the knockout pool preserves genetic diversity, making it particularly suitable for population-level studies of tumor cell behavior, signaling pathway analysis, and drug response profiling. By abolishing KCTD1 expression, the cells offer a robust platform for investigating the gene??s roles in transcriptional regulation, ubiquitin-mediated degradation, and epithelial homeostasis.
HT29 cells, derived from a primary colorectal adenocarcinoma of a 44-year-old Caucasian female, constitute a well-characterized intestinal epithelial model widely employed in cancer research. These adherent epithelial cells exhibit anchorage-independent growth and express markers typical of colorectal tumors, rendering them an ideal system for studying colorectal cancer progression, metastasis, and therapeutic resistance. The HT29 line??s genetic background includes mutations in key oncogenic pathways, and their capacity for forming polarized monolayers allows investigation of cell adhesion and invasion mechanisms. Thus, KCTD1 knockout in this context provides a physiologically relevant cellular environment for dissecting the gene??s contribution to malignant phenotypes.
KCTD1 functions as a substrate adaptor for the CUL3-RING E3 ubiquitin ligase complex, specifically targeting the transcription factor TFAP2A for ubiquitination and subsequent proteasomal degradation. By promoting TFAP2A turnover, KCTD1 represses AP-2-mediated transcription of crucial developmental and adhesion genes such as CDH1 (E-cadherin) and MMP2 (matrix metalloproteinase 2). This molecular axis is regulated by upstream signals including BMP4 and WNT3A, and involves interactions with CUL3 and KCTD15. In the context of craniofacial development and neural crest specification, KCTD1-mediated control of TFAP2A levels is essential for proper cell fate determination, and its dysregulation has been linked to Scalp-Ear-Nipple syndrome.
In the HT29 colorectal adenocarcinoma model, KCTD1 knockout is expected to disrupt the balance of AP-2 signaling, potentially leading to altered expression of CDH1 and MMP2, which are critical for cell adhesion and matrix remodeling. Such perturbations can modulate epithelial-mesenchymal transition (EMT), migration, and invasive capacity??hallmarks of colorectal cancer metastasis. Consequently, these polyclonal knockout cells serve as a valuable tool for dissecting how KCTD1 influences tumor progression through the ubiquitin-proteasome pathway. Moreover, they enable the study of cross-talk between developmental signaling cascades and oncogenic processes in an epithelial context relevant to human disease.
Researchers can employ these cells in a variety of functional assays, including western blotting and RT-qPCR to confirm knockout efficiency and downstream target expression, co-immunoprecipitation for probing CUL3 or TFAP2A interactions, ubiquitination assays to monitor TFAP2A turnover, and reporter gene assays to measure AP-2 activity. Cell proliferation and migration assays, coupled with immunofluorescence for EMT markers, provide direct readouts of phenotypic changes. The model is ideally suited for drug screening campaigns aimed at identifying modulators of the KCTD1?CTFAP2A interaction or ubiquitin ligase activity, and for broader epithelial cell biology studies investigating signal-dependent protein degradation. For additional technical information, please contact Ascent Research.
